BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24612093)

  • 1. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate.
    Wu JY; Hsu PI; Wu DC; Graham DY; Wang WM
    Helicobacter; 2014 Jun; 19(3):207-13. PubMed ID: 24612093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Helicobacter; 2016 Oct; 21(5):382-8. PubMed ID: 26809022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
    Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
    Tepeš B; Vujasinović M; Šeruga M; Stefanovič M; Forte A; Jeverica S
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):676-83. PubMed ID: 26862930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial.
    Heo J; Jeon SW; Jung JT; Kwon JG; Lee DW; Kim HS; Yang CH; Park JB; Park KS; Cho KB; Lee SH; Jang BI;
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1361-6. PubMed ID: 25867608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial.
    Tsay FW; Wu DC; Kao SS; Tsai TJ; Lai KH; Cheng JS; Chan HH; Wang HM; Tsai WL; Tseng HH; Peng NJ; Hsu PI
    Helicobacter; 2015 Feb; 20(1):71-7. PubMed ID: 25495272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
    Georgopoulos S; Papastergiou V; Xirouchakis E; Laoudi F; Lisgos P; Spiliadi C; Papantoniou N; Karatapanis S
    J Clin Gastroenterol; 2013 Mar; 47(3):228-32. PubMed ID: 22858517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
    Lim JH; Lee DH; Choi C; Lee ST; Kim N; Jeong SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Jo HJ; Jang ES; Song Is; Jung HC
    Helicobacter; 2013 Jun; 18(3):180-6. PubMed ID: 23305083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
    Prasertpetmanee S; Mahachai V; Vilaichone RK
    Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand.
    Kongchayanun C; Vilaichone RK; Pornthisarn B; Amornsawadwattana S; Mahachai V
    Helicobacter; 2012 Aug; 17(4):282-5. PubMed ID: 22759328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.
    Mestrovic A; Perkovic N; Bozic J; Pavicic Ivelja M; Vukovic J; Kardum G; Puljiz Z; Tonkic A
    PLoS One; 2020; 15(12):e0244500. PubMed ID: 33378403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori eradication in a developing country.
    Fischbach LA; Bravo LE; Zarama GR; Bravo JC; Ojha RP; Priest EL; Collazos T; Casabon AL; Guerrero LZ; Singh KP; Correa P
    Helicobacter; 2009 Apr; 14(2):100-8. PubMed ID: 19298337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.
    Chung JW; Jung YK; Kim YJ; Kwon KA; Kim JH; Lee JJ; Lee SM; Hahm KB; Lee SM; Jeong JY; Yun SC
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1675-80. PubMed ID: 22849546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
    Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
    Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication.
    Sierra F; Forero JD; Rey M; Botero ML; Cárdenas A
    Aliment Pharmacol Ther; 2013 Jun; 37(12):1165-71. PubMed ID: 23656465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.